The study aim was to investigate the health effects of a pedometer-based behavioural modification program in type 2 diabetes patients and to examine the relationship between changes in steps/day (baseline-post and baseline-follow up) and health outcomes. Ninety-two type 2 diabetes patients (69% male, mean age: 62 ± 9 years and mean BMI: 30.0 ± 2.5 kg/m 2 ) were recruited and randomly assigned to an intervention or control group. The intervention consisted of one face-to-face session, pedometer use and seven telephone calls. Selection criteria included 35-75 years, 25-35 kg/m 2 and 12% HbA 1c (108 mmol/mol). Outcome measures were assessed at baseline, post and follow up, and included systolic blood pressure, waist circumference, body mass index, glucose control (HbA 1c and fasting glucose), triglycerides, total, HDL and LDL cholesterol and steps/day. The results showed no significant short-or intermediate-term differences in health outcomes between the control and intervention group. However, a threshold was identified, as HbA 1c improved significantly in those who increased !4000 steps/day between baselineand post-measurements (n ¼ 18). This threshold was not applicable to any other health outcome. Hence, although the intervention successfully increased steps/day, no direct effect on health outcomes was identified. However, an increase of !4000 steps/day seemed a threshold to have a positive impact on HbA 1c .
Introduction
Along with diet and medication, physical activity (PA) can be considered as a cornerstone of diabetes management (i.e. attaining glucose control). Glucose control is highly effective in attenuating the development and progression of the long-term complications of diabetes [1] . The magnitude of the improvement in glucose control attributable to PA is generally modest but clinically important (a decrease in % glycated haemoglobin [HbA 1c %] of 0.5-1%) [2] .
To facilitate PA changes in type 2 diabetes patients, pedometers are frequently used in interventions. Pedometers have proven their usefulness to increase PA levels (expressed in steps/day) in populations known to have little interest in, and high dropout rates from formal exercise programs, like type 2 diabetes patients [3, 4] . The most important benefits of using pedometers as a motivational tool are the immediate feedback they give and the fact that aiming to take a predefined number of steps/day is a clear and understandable goal. In general populations, the most widely recognized step recommendation to improve health is to accumulate 10 000 steps/day [5] . However, this guideline may be unrealistic for type 2 diabetes patients. Tudor-Locke et al. [6] postulated that it is more appropriate to work with gradual increases, based on the baseline number of steps in this target group.
In previous studies, no improvements in glucose control (as determined by HbA 1c changes) due to increases in steps/day could be identified [7] [8] [9] , which may be attributed to minimal intervention effects on PA (steps/day).
We developed and evaluated a pedometer-based behavioural modification program in type 2 diabetes patients that showed a pronounced effect on PA. The participants of the intervention group increased their steps/day with on average 1872 steps and those of the control group decreased with on average 1275 steps/day (F ¼ 55.7, P 0.001) [10] .
Because of these strong intervention effects on PA, a first purpose of this follow-up analysis is to examine if our behavioural modification program had a positive effect on health parameters [systolic blood pressure, waist circumference, body mass index (BMI), glucose control (HbA 1c and fasting glucose), triglycerides, total, HDL and LDL cholesterol]. Second, to discover if a dose-response relationship between increases in step counts and health effects exists (e.g. 2000 steps/day increase is needed before health effects can be found), we examined the relationship between changes in steps/day (between baseline-and post-measurements; between baseline-and follow up-measurements) and health outcomes. This second aim is important to establish clear and understandable health-related PA guidelines for type 2 diabetes patients and clinicians.
Methods
A description of the study protocol and the intervention was reported elsewhere [10] . Ninety-two type 2 diabetes patients [35-75 years, 25-35 kg/m 2 , 12% HbA 1c (108 mmol/mol), no PA limitations] were recruited through the endocrinology department of the Ghent University Hospital. They were randomly assigned to a PA intervention (n ¼ 60) or a (usual care) control group (n ¼ 32) using a 2:1 randomization ratio. Unequal randomization was applied because the number of eligible patients at the Ghent University Hospital was limited (143 potential participants). By using a 2:1 randomization ratio, the number of patients possibly benefiting from the intervention was maximized, and the power to conduct secondary analyses using only participants of the intervention condition was increased. The intervention was lead by a psychologist and based on the principles of cognitive-behavioural therapy [11] , the Diabetes Prevention Program [12] , the First Step Program [13] and Motivational Interviewing [14] . The intervention consisted of a face-to-face session, the use of pedometers and seven telephone calls (individually tailored motivational interviewing and duration of calls ranged from 15 to 20 min), spread over a 24-week period. The telephone support followed specific, but flexible scripts and was constructed to include counselling on goal setting, self-monitoring, self-efficacy, benefits, decisional balance, problem-solving strategies, social support and relapse prevention. The pedometer was used as a monitoring tool and was a crucial component of the intervention. Participants were asked to wear the pedometer and to record their number of steps as well as the type and duration of non-walking activities in a pedometer log book at the end of each day. Following established guidelines, 150 steps were added to the daily total for every minute of reported cycling or swimming [15] . The pedometer and log book were used to track progress in PA. For most participants, a gradual increase in PA, starting from
their baseline levels, was used. Health outcomes and pedometer-based step counts were assessed at three moments: baseline, immediately after the 24-week intervention (short-term effects) and 1 year after baseline (intermediate-term effects). The Ethical Committee of the Ghent University Hospital approved this study.
Health outcomes
Standing waist circumference was measured at the narrowest point of the torso between the rib cage and the iliac crest. Body weight and height were measured wearing light clothing and without shoes. Waist circumference, body weight and height were measured twice, and the average of the two measurements was used in further analyses. Systolic blood pressure was measured with an Omron M6 in seated position after 5 min of resting. The Omron M6 was routinely calibrated. Blood samples were taken according to hospital laboratory protocols. The hexokinase method was used to analyse fasting glucose and the Adams Haemoglobin A 1c procedure was used for HbA 1c . Total cholesterol, HDL and LDL cholesterol and triglycerides were analysed with enzymatic colorimetric analyses.
Step counts were assessed using the Yamax DigiWalker SW200 pedometer, a tool that has proven its validity and reliability [16] . All participants wore the pedometer for five consecutive days (including at least one weekend day) at the waist, above the right hipbone. Participants were asked to wear the pedometer during waking hours, and to remove it only for water-based activities and sleeping. After each wearing day, participants reported their steps in a log book.
Statistical analyses
Analyses were performed using SPSS 19.0 for Windows. Repeated-measures ANOVAs with baseline carried forward intention-to-treat principles were used to evaluate intervention effects on health outcomes (baseline-post/short-term and baselinefollow up/intermediate-term effects; Table I ). As no differences in demographic and descriptive characteristics were found between the control group and the intervention group at baseline, no covariates were included in the analyses. Second, to examine the associations between changes in steps/day and changes in health outcomes, ANCOVAs were performed. Changes in health outcomes (baseline-post and baseline-follow up) were included as dependent variables. Groups based on absolute steps/day at the end of the treatment (post and follow up) were included as between factors (e.g. group reaching 7500 steps/day at post-measurements versus group not reaching 7500 steps/day; separate models for every additional 500 steps/day), and covariates were added as specified in Table II . Different thresholds were thus studied in the different models, for example, change in HbA 1c was analysed between the group reaching versus the group not reaching 10 000 steps/day after the intervention or between the groups reaching versus not reaching 9500 steps/ day (separate models for post-measurements and for follow up-measurements).
The same procedure was followed with incremental differences in steps/day between baseline-and post-measurements and baseline-and follow up-measurements as between factors (e.g. increase of >3000 steps/day versus increase of <3000 steps/ day; separate model for every relative increase of 500 steps/day).
Results
Mean age of the sample was 62 ± 9 years, mean BMI 30 ± 2.8 kg/m 2 , 69% was male, 82% diagnosed >5 years, 44% took a combination of oral medication and insulin. Mean systolic blood pressure was 132.3 ± 15.6 mmHg, HbA 1c 7.3 ± 0.9%, fasting glucose 138.8 ± 36.3 mg/dl and total cholesterol 168.0 ± 28.7 mg/dl. No differences in descriptive or demographic characteristics at baseline between the control and intervention group were found. Only two patients in each group dropped out.
Although the intervention had clear short-(baseline-post) and intermediate-term (baseline-follow up) effects on steps/day, no differences in change in any health outcomes between the intervention and control group were found (all P > 0.05; see Table I ).
Health effects of a telephone counselling intervention
However, an increase of !4000 steps/day between baseline-and post-measurements (n ¼ 18) was associated with a 0.2% decrease in HbA 1c % (decrease of 21 mmol/mol), whereas a smaller increase [<4000 steps/day (n ¼ 74)] resulted in an increase of 0.3% in HbA 1c % (increase of 20 mmol/ mol) (P ¼ 0.024). For all other incremental differences (baseline-post and baseline-follow up measurements), no significant differences in HbA 1c changes between the group reaching versus the group not reaching the studied thresholds were found (all P > 0.05). Moreover, there were no differences in any of the health outcomes according to any absolute change in number of steps/day (all P > 0.05), both for the baseline-post and baselinefollow up analyses. Likewise, an increase of !4000 steps/day seemed no threshold for any other health outcome besides HbA 1c (see Table II , baselinefollow up results not shown).
Discussion
Despite its clear effects on PA [10] , this pedometerbased behavioural modification program did not have a significant impact on any of the measured health outcomes. Our results are in contrast with other studies where the effect of PA-based behavioural modification programs on health outcomes (primarily HbA 1c ) was relatively small but significant [17] . Nonetheless, in these interventions mainly high-intensity PA was targeted. Johnson et al. [18] suggested that an increase in daily step counts may be insufficiently intense to achieve improvements in health outcomes. This may be the case in this study. Another explanation could be the relative difficulty to dissociate the effects of an increase in PA on health outcomes from the effects of adjustments in medication and diet. Our trial included type 2 diabetes patients who were treated in a University hospital, strictly regulated by endocrinologists. It could be that the patients were so well controlled (e.g. mean baseline HbA 1c was 7.3% or 56 mmol/mol), that it was not possible to establish any additional health effect with our PA intervention [19] . In another study with a similar population much higher baseline levels in systolic blood pressure, HbA 1c and cholesterol were observed [20] . Moreover, it is possible that the patients overcompensated for their energy expenditure by eating more or differently. This hypothesis cannot be checked using the present data, as no information on eating habits was collected. An increase of 4000 steps/day seemed to be a threshold stimulus necessary to have a significant impact on HbA 1c in type 2 diabetes patients. Covariates: age, years since diagnosis, insulin use, baseline step counts and change scores between pre-and post-measurements in HbA 1c and total cholesterol. *P < 0.05. All means are change scores between pre-and post-measurements. !4000 steps/day: n ¼ 18, <4000 steps/day: n ¼ 74.
Health effects of a telephone counselling intervention
Consequently, it may be plausible that to improve glucose control, type 2 diabetes patients need to increase their steps/day with more than the 2000-2500 extra steps/day that are typically expected of pedometer-based interventions in general populations [4] . However, the positive effects of a 4000 steps/day increase on HbA 1c could only be identified on the short-term (baseline-post); no such effects were found when comparing baseline with follow-up measurements. A possible explanation for this finding could be that the positive short-term effects on HbA 1c in those patients who increased their PA with more than 4000 steps/day may have led to adjustments to their medication (insulin, diabetes medication), possibly inducing a lack of effects of step count increases on HbA 1c on the intermediate term.
An important consideration to take into account is whether a difference of 0.5% HbA 1c (18 mmol/mol) between the group increasing 4000 steps/day or more and the group increasing <4000 steps/day is clinically relevant. In the United Kingdom Prospective Diabetes Study (UKPDS), intensive glucose control with meformin reduced HbA 1c by 0.6% (17 mmol/mol). This seemed sufficient to reduce the risk of diabetes-related complications by 32% and the risk of diabetes related mortality by 42% [21] . Although the difference in HbA 1c in this study was lower than 0.6% (17 mmol/mol) between the group increasing more than 4000 steps and group increasing <4000 steps/day (0.5%, 18 mmol/mol), it might be that a greater reduction in cardiovascular complications can be anticipated with a PA intervention compared to treatments with medications, since PA is associated with other cardiovascular benefits and does not cause weight gain. Moreover, Bloomgarden et al. concluded that it would be excessively optimistic to expect a reduction of 0.6% (17 mmol/mol) in type 2 diabetes patients whose initial HbA 1c level was <7.5-8% (58-64 mmol/mol) (HbA 1c in this study group: 7.3%, 56 mmol/mol) [19] . Furthermore, achieving better glucose control has been associated with decreased micro-vascular events such as retinopathy, nephropathy and neuropathy [22] . Since HbA 1c is the most important indicator of glucose control in type 2 diabetes patients [1, 2, 17] , the small effect found in this study may be meaningful.
Conclusion
Despite its clear effects on PA [10] , this pedometer-based behavioural intervention had no direct effects on any of the measured health outcomes in this generally well-controlled group of type 2 diabetes patients. However, enhanced glucose control was realized in those who achieved an increase of !4000 steps/day over baseline values. These results may be important for researchers to develop future studies examining health effects of behavioural interventions in type 2 diabetes patients. Furthermore, if interpreted with caution, the findings may be useful for practitioners as well.
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